Last reviewed · How we verify
Xyvion (TIBOLONE)
Xyvion works by binding to the sodium-dependent serotonin transporter, which helps regulate serotonin levels in the body.
Xyvion, also known as tibolone, is a small molecule drug that targets the sodium-dependent serotonin transporter. It is classified as a tibolone and has been approved for the treatment of postmenopausal osteoporosis. The commercial status of Xyvion is currently unknown, and it is not clear if it is patented or available as a generic medication. As a pharma professional, it is essential to consider the potential safety implications of Xyvion, although specific details are not available. Further research is necessary to fully understand the pharmacological properties of Xyvion.
At a glance
| Generic name | TIBOLONE |
|---|---|
| Drug class | tibolone |
| Target | Sodium-dependent serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Bone |
| Phase | discontinued |
Mechanism of action
Think of serotonin as a chemical messenger that helps regulate mood, appetite, and sleep. When Xyvion binds to the sodium-dependent serotonin transporter, it can affect how much serotonin is available in the body, which may help alleviate symptoms of postmenopausal osteoporosis.
Approved indications
- Postmenopausal osteoporosis
Common side effects
Key clinical trials
- A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469) (PHASE3)
- Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Postmenopausal Women (P06090) (PHASE4)
- HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness
- Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids
- the Effects of Different Therapy Regimens on Menopausal Sleep Disorders (PHASE4)
- The Effects of Luo-Bu-Fu-Ke-Bi-RI Pill
- The Impact of Hormone Therapy on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder (PHASE4)
- Efficacy of Tibolone Versus Transdermal E2/NETA on Sexual Function in Naturally Postmenopausal Women (P06089) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xyvion CI brief — competitive landscape report
- Xyvion updates RSS · CI watch RSS